A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects with Unresectable, Advanced, and/​or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Trial Identifier: NT-112-301
Sponsor: AstraZeneca
Start Date: April 2024
Primary Completion Date: August 2027
Study Completion Date: August 2042
Condition: Colorectal Cancer; Endometrial Cancer; Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Duarte, CA, US, 91010
US, CA Los Angeles, CA, US, 90095
US, CA Newport Beach, CA, US, 92663
US, KS Westwood, KS, US, 66205
US, MO Saint Louis, MO, US, 63110
US, NY New York, NY, US, 10016
US, PA Pittsburgh, PA, US, 15237
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75246
US, TX Galveston, TX, US, 77555
US, TX Houston, TX, US, 77030
US, WA Aberdeen, WA, US, 98520
US, WI Milwaukee, WI, US, 53226